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ABSTRACT
Objective: Basal metabolic rate (BMR) is the most
important indicator of human metabolism and its
abnormalities have been linked to undesirable health
outcomes. Cigarette smoking associates with increased
BMR in healthy individuals; it is also related with worse
disease outcomes in patients with rheumatoid arthritis
(RA), in whom BMR is high due to hypercatabolism
caused by systemic inflammation. We aimed to
investigate whether smokers with RA demonstrated
higher BMR levels than their non-smoking counterparts.
Methods: A total of 53 patients with RA (36 female, 17
male, 20 current smokers) were assessed for: BMR
(indirect calorimetry), anthropometrical data, fat-free
mass (bioelectrical impedance), physical function (health
assessment questionnaire; HAQ) and disease activity
(disease activity score DAS28 and C reactive protein).
Results: RA smokers and non-smokers were not
significantly different for age, height, weight, body mass
index and fat-free mass. Compared to non-smokers,
smokers with RA demonstrated significantly higher BMR
(mean (SD) 1513.9 (263.3) vs 1718.1 (209.2) kcal/day;
p,0.001) and worse HAQ (1.0 (0.8) vs 1.7 (0.8);
p = 0.01). The BMR difference was significantly predicted
by the interaction smoking/gender (p = 0.04). BMR was
incrementally higher in light, moderate and heavy smokers
(p = 0.018), and correlated with the daily number of
cigarettes smoked (r = 0.68, p = 0.04).
Conclusion: Current cigarette smoking further increases
BMR in patients with RA and has a negative impact on
patients’ self-reported functional status. Education
regarding smoking cessation is needed for the RA
population.
Basal metabolic rate (BMR), the main indicator of
human metabolism, is a vital physiological func-
tion providing for bioenergetics, body composition
and by-product removal, and is largely affected by
perturbations of the body’s internal and/or exter-
nal environment.1 Inflammatory disease,2 3 cancer,4
human immunodeficiency virus infection,5 critical
illness,6 as well as active7 and passive8 smoking are
factors that significantly increase BMR and disturb
normal metabolic processes.
Rheumatoid arthritis (RA), the commonest
chronic inflammatory joint disease, is accompanied
by a set of metabolic abnormalities collectively
referred to as rheumatoid cachexia. This abnormal
metabolic response is mainly due to excessive
production of tumour necrosis factor alpha
(TNFa): this causes significant elevation in BMR
and enhances protein catabolism, resulting in
involuntary and rapid wasting of muscle mass.9
Rheumatoid cachexia has also been closely asso-
ciated with augmented abdominal fat deposition10
increased cardiovascular risk,2 and compromised
muscle strength, balance and functional ability; as
such, it is a significant overall contributor to co-
morbidity and reduced life-expectancy in RA.11
Ideally, any factors associated with increasing
metabolism in RA should be identified and, if
possible, eliminated early in the course of the
disease.
In healthy subjects, current cigarette smoking
significantly augments resting metabolism.12 The
impact of smoking on BMR has not been assessed
in patients with RA. However, smoking has been
implicated in the aetiology,13 14 severity15 and
cardiovascular co-morbidity16 17 of this disease.
The aim of the present study was to investigate
whether RA patients who are current cigarette
smokers have higher BMR levels than RA patients
who have never smoked.
METHODS
Participants
A total of 53 consenting volunteers (36 females, 17
males; 20 current cigarette smokers, 33 non-
smokers) with RA were recruited from rheumatol-
ogy outpatient clinics of the Dudley Group of
Hospitals NHS Trust in the UK. All patients met
the retrospective application of the revised 1987
American College of Rheumatology (ACR) classi-
fication criteria18 as well as the inclusion and
exclusion criteria for this study (table 1). The
presence or absence of inclusion/exclusion criteria
was on the basis of patient history and was further
verified by review of hospital and, where necessary,
primary care notes, all their medications and
relevant blood tests (eg, thyroid function tests,
fasting glucose, liver function tests). The patients
included in this study comprised a subgroup of a
larger group of 82 RA patients recruited consecu-
tively from these clinics for assessment of BMR, as
part of another study. The present study however,
included only patients who had never smoked or
were current cigarette smokers: ex-smokers, and
patients smoking cigars, pipes or other substances
were excluded. Smokers were further divided into
three subgroups according to the number of
cigarettes smoked per day (light smokers: ,5,
moderate smokers: 5–9, heavy smokers: >10). RA
patients had to be on stable medication for at least
3 months prior to assessment.
Information was given to all participants in
verbal and written format, and a special follow-up
visit was arranged in the rheumatology research
unit for final consent and assessment. The study
had prior approval by the local research ethics
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committee and the Dudley Group of Hospitals Research and
Development Directorate.
Procedures
All participants attended a single 2 h laboratory session after
visiting the data collection site early in the morning (8:00–9:00
a.m.) following a 12-h overnight fast. Demographic and
anthropometrical characteristics were recorded first, BMR was
measured next, and a blood sample with assessment of the
disease activity score (DAS28)19 and health assessment ques-
tionnaire (HAQ) were performed last. Standing height was
measured to the nearest 0.5 cm (Seca Stadiometer 208, Vogel &
Halke, Hamburg, Germany). Body mass was measured to the
nearest 0.1 kg and body composition was evaluated by
bioelectrical impedance, using a segmental body composition
analyser (Tanita BC 418 MA, Tanita, Tokyo, Japan). Several
other methods for assessing body composition, such as dual
energy x ray absorptiometry, underwater weighing, total body
water, and total body nitrogen may be superior for studies
assessing specifically body composition,20 21 but are cumbersome
and require specialised equipment and personnel. Bioelectrical
impedance, particularly based on eight electrodes as in this
study, has been shown to be accurate in the general population22
as well as in patients with RA,20 and has the advantage of
simplicity and reproducibility in the routine clinical setting.10
BMR was measured via indirect calorimetry, adhering to well-
described methodological standards.23 Participants rested for a
20-min period prior to the measurement in a semi-darkened,
quiet and thermoregulated (22uC) room. An automated gas
analyser (Metalyzer, Cortex Biophsik, Borsdorf, Germany),
calibrated before each test using standard gases of known
concentration, was used to record respiratory parameters every
20 s, while subjects inspired room air through a free-breathing
face mask. Data were collected over a period of 40 min with the
participants being instructed to refrain from sleeping or
hyperventilating. Mean values of BMR for that period excluding
the first and last 5 min were calculated using the Weir
equation.24 Contemporary RA disease activity was measured
using the erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP), both routinely measured in the laboratories of
the Dudley Group of Hospitals; and clinically using the DAS2819
performed by a single specialist metrology nurse. Disease
severity (reflected in physical dysfunction) was assessed using
the HAQ. Disease duration (from symptom onset) was
recorded.
Statistical analyses
Routine pre-analysis screening using the Kolmogorov–Smirnov
normality tests were conducted to detect whether the studied
variables were normally distributed. Comparisons between RA
smokers and non-smokers for the three not normally distributed
variables (ie, disease duration, CRP and ESR in table 2) were
conducted using non-parametric tests (Mann–Whitney U test),
and results are presented as median (range). All other (normally
distributed) variables were compared using parametric statistics
(Student t tests) and results are presented as mean (SD). For
statistically significant differences in normally distributed
variables between the smoker and non-smoker RA groups, the
95% confidence intervals (95% CI) are also reported. One-way
ANOVA was adopted to examine whether mild, moderate and
heavy RA smokers had different levels of BMR. Pearson’s and
Spearman’s correlations were employed, as appropriate, to
assess whether parameters previously reported to influence
BMR, ie demographic (gender, age), anthropometrical (height,
weight, body mass index (BMI) and fat-free mass (FFM)) and
disease related (CRP, DAS28, ESR)1 2 9 25 showed associations
with BMR in these RA patients. ANCOVA was used to detect if
smoking was a significant factor influencing BMR after
adjusting for variables that were found to significantly influence
BMR. All statistical analyses were conducted using SPSS
(version 13.0.1, Chicago, Illinois, USA), and statistical signifi-
cance was set at p,0.05.
RESULTS
Demographic, anthropometrical and disease-related character-
istics, are shown in table 2. There were no significant differences
between RA smokers and non-smokers in any of the parameters
assessed apart from disease severity as assessed by the HAQ and
BMR: HAQ physical disability was significantly worse (mean
(SD) 1.66 (0.8) vs 1.04 (0.8); p=0.01, 95%CI21.1 to 20.1), and
BMR was significantly higher (1718.1 (209.2) vs 1513.9
(263.3) kcal/day; p,0.001, 95% CI2343.4 to 265.1) in smokers
compared to non-smokers (table 2). Within RA smokers, BMR
levels were significantly different between the light (1523.8
(192.3) kcal/day), moderate (1723.4 (180.7)) and heavy (1850.7
(154.6) kcal/day) smokers (p=0.018). The number of cigarettes
smoked correlated significantly with BMR (r=0.61, p=0.04).
A similar, but non-significant (p.0.05), difference was found
for the HAQ between light (1.4 (0.9)) moderate (1.6 (0.9)) and
heavy (1.9 (0.8)) smokers.
In the entire cohort of RA patients (n=53), BMR showed
significant correlations with age (r=20.36, p=0.008), height
(r=0.59, p,0.001), weight (r=0.71, p,0.001), BMI (r=0.51,
p,0.001) and FFM (r=0.72, p,0.001). In addition, BMR
significantly correlated with CRP and DAS28 (r=0.36,
p=0.008 and r=0.27, p=0.47, respectively). ANCOVA
showed that after adjustment for the factors that significantly
correlated with BMR, the difference in BMR was significantly
attributed to the association of smoking/gender (F1,38=4.3,
p,0.05) but not either of these factors alone (smoking
F1,38=0.59, p.0.05; gender F1.38=0.14, p.0.05); despite the
fact that, no significant differences were observed in the factors
that influence resting metabolism between female smokers and
non-smokers (mean (SD) age: 57.1 (13.6) vs 62.9 (10.9) years;
BMI: 25.4 (5.9) vs 25.7 (4.1) kg/m2, FFM: 41.6 (6.0) vs 40.5
Table 1 Inclusion and exclusion criteria for the current rheumatoid
arthritis (RA) patients
Inclusion criteria Exclusion criteria
Patients fulfilling 1987 American
College of Rheumatology
classification criteria for RA,
irrespective of age, sex, disease
activity, disease duration, treatment
or anthropometrical characteristics.
Hyper- or hypothyroidism
On stable medication for >3 months
prior to assessment
Diabetes mellitus
Malabsorption of any cause
Chronic liver failure
Pregnancy
Current or chronic diarrhoea
Proteinuria
Obstructive or restrictive lung disease
Congestive heart failure
Current infection
Ex-cigarette smokers, or current cigar,
pipe or other substance smokers
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(4.0) kg; CRP: 11.0 (6.0–38.0) vs 10.0 (6.0–14.0) mg/L, respec-
tively, all at p.0.05), BMR was significantly increased in the
former group (female smokers: 1652.2 (202.4) vs non-smokers:
1452.1 (180.7) kcal/day, respectively, p=0.001 and 95% CI
2394.1 to 120.4). A similar trend was observed in males
(smokers: 1810.4 (101.6) vs non-smokers: 1690.6 (327.1) kcal/
day), however, this was not significant (p.0.05). Smoking
appeared to be a more powerful predictor of BMR than either
CRP (F1,38=1.0, p=0.31) or DAS28 (F1,38=0.03, p=0.86).
DISCUSSION
This study shows that current cigarette smokers with RA have
significantly higher BMR than patients with RA who have
never smoked. As previously described in normal1 9 25 and
diseased26–29 populations, BMR in the total group of RA patients
studied here was influenced by several demographic and
anthropometrical characteristics (including age and FFM), as
well as inflammatory disease activity2 3 9 The groups of RA
smokers and non-smokers were not significantly different for
any of these characteristics, and the difference in BMR remained
robust even after statistical adjustment for them, suggesting
that it was predominantly, if not exclusively, due to smoking.
The expected BMR in healthy normal individuals of similar
age and anthropometrical characteristics to the patients studied
here would be approximately 1400 kcal/day.30 RA non-smokers
in this study had a mean BMR 8% higher (just over 1500 kcal/
day) while RA smokers demonstrated a mean BMR 20% higher
than this (over 1718 kcal/day). A BMR increase of more than
12% above normal levels has been reported to have detrimental
health implications, particularly when the extra energy derives
from muscle catabolism.2 3 Active RA9 or smoking31 may
independently or in tandem result in loss of FFM, leading to
compromised muscle strength and balance, functional disabil-
ity, and immune dysfunction.11 It seems reasonable to suggest
therefore, that through such a mechanism, smoking may
further enhance the deleterious consequences of ongoing
inflammation in RA, and this would be partly supported by
the finding in the present study that RA smokers had worse
physical function than non-smokers, as assessed by the HAQ.
The suggestion that smoking plays an important role is
further supported by the finding that smoking appears to be a
stronger predictor of increased BMR than disease activity, and
of a stepwise BMR increase between light, moderate and heavy
smokers, together with the direct significant correlation
between BMR and the number of cigarettes smoked, and the
finding that the smoking/gender interaction is a significant
predictor of BMR. These results reveal that it is female patients
that have the most pronounced effects in BMR as a result of
smoking; the same trend was observed in males but it was not
statistically significant, probably due to the small number of
male smoking RA patients included in this study. Overall, these
findings suggest that smoking causes a dose-dependent increase
in BMR, which is in line with previous reports in normal
populations.7 12 Acute (eg, immediate increase in oxygen
demand32) and chronic (eg, elevated thyroxin levels33) physiolo-
gical changes due to smoking may account for increases in BMR.
Smoking in RA has attracted considerable research interest for
many years. Smoking is a factor that has been linked to the
aetiopathogenesis of the disease,34–37 particularly in the context
of concurrent genetic predisposition.13 14 It appears to associate
with greater disease activity and overall severity15 38 39 as well as
extra-articular manifestations including rheumatoid nodules,40
vasculitis17 and accelerated atherosclerosis.16 Smoking has also
been linked to imbalances in the production of TNFa and
soluble TNF receptors, leading to a relative excess of TNFa.41
This may be one of the mechanisms leading to the increased
hypermetabolism specifically in RA smokers, as observed in the
present study.
Although this study did not intent to identify the clinical
implications of the increased BMR due to smoking, it could be
argued that the significant increase in HAQ, suggests that
smoking negatively affects the patients’ self-reported functional
status. Smoking, together with age, gender, education, exercise,
BMI and number of co-morbidities, have previously been
described as important determinants of HAQ disability.42
Hypermetabolism in RA has also been linked to increased
disability, reduced quality of life and premature mortality:2 11 it
is likely that the additional smoking-induced elevation of BMR
will have further negative effects (eg, increased protein
catabolism) on the health status of this population. The present
findings add further reasons to suggest that the RA population
has to be specifically targeted for smoking cessation.43
Acknowledgements: The Department of Rheumatology, Dudley Group of Hospitals,
has an infrastructure support grant from the Arthritis Research Campaign (no. 17 682).
Table 2 Demographic, anthropometric and disease-related characteristics for the rheumatoid arthritis (RA) patients assessed in this study
RA Smokers (n= 20) p RA non-smokers (n=33) Total RA (n=53)
Demographic
Gender
Males 5 – 12 17
Females 15 21 36
Age (years, mean (SD)) 58.2 (12.0) 0.07 64.1 (11.2) 61.9 (11.7)
Anthropometrical
Height (cm, mean (SD)) 164.5 (9.8) 0.26 161.6 (8.8) 162.7 (9.2)
Weight (kg, mean (SD)) 72.5 (19.7) 0.32 67.7 (15.0) 69.5 (16.9)
Body mass index (kg/m2, mean (SD)) 26.2 (5.8) 0.69 25.7 (4.4) 25.9 (4.9)
Fat free mass (kg, mean (SD)) 45.8 (10.8) 0.46 44.6 (9.4) 45.1 (9.8)
Disease-related
C-reactive protein (mg/L) 14.5 (7.2–35.2) 0.22 10.0 (7.0–18.0) 10.0 (7.0–27.0)
Disease activity score 28 (mean (SD)) 4.6 (1.5) 0.14 4.1 (1.1) 4.3 (1.2)
Erythrocyte sedimentation rate (mm/first h) 24.5 (10.5–41.7) 0.58 20 (10.5–31.0) 22.0 (10.5–35)
Disease duration (years) 7.5 (5.2–19) 0.94 10.0 (3.0–16.0) 9.0 (5.0–16.0)
Health assessment questionnaire (mean (SD)) 1.7 (0.8) 0.01 95% CI 21.1 to 20.1 1.0 (0.8) 1.3 (0.9)
Basal metabolic rate (kcal/day, mean (SD)) 1718.1 (109.2) ,0.001 95% CI 2343.4 to 265.1 1513.8 (263.3) 1590.9 (262.0)
Significant differences were only detected between BMR and HAQ between smokers and non-smokers with RA.
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